All In Biotech

Drug Trial Radar · NCT01629667

A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: May 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 409 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

409

Actual

Start

Oct 2012

Primary completion

May 2015

Study completion Jan 2016

Sponsor

Lead sponsor
MedImmune LLCAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (IPF). IPF is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • TralokinumabBiological

    Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.

  • TralokinumabBiological

    Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.

  • PlaceboOther

    Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 52Time frame: Baseline and Week 52

Locations

45 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    La Jolla, California

  • Research Site

    Sacramento, California

  • Research Site

    Tampa, Florida

  • Research Site

    Winter Park, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Honolulu, Hawaii

  • Research Site

    Chicago, Illinois

  • Research Site

    Louisville, Kentucky

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    Chesterfield, Missouri

  • Research Site

    Summit, New Jersey

  • Research Site

    Durham, North Carolina

  • Research Site

    Hershey, Pennsylvania

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Charleston, South Carolina

  • Research Site

    Nashville, Tennessee

  • Research Site

    McAllen, Texas

  • Research Site

    McKinney, Texas

  • Research Site

    Salt Lake City, Utah

  • Research Site

    Box Hill, Australia

  • Research Site

    Camperdown, Australia

  • Research Site

    Concord, Australia

  • Research Site

    Darlinghurst, Australia

  • Research Site

    Frankston, Australia

  • Research Site

    Glen Osmond, Australia

  • Research Site

    New Lambton, Australia

  • Research Site

    Parkville, Australia

  • Research Site

    Prahran, Australia

  • Research Site

    Woodville South, Australia

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    Windsor, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Québec, Quebec, Canada

  • Research Site

    Ashkelon, Israel

  • Research Site

    Haifa, Israel

  • Research Site

    Jerusalem, Israel

  • Research Site

    Petah Tikva, Israel

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.